<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869491</url>
  </required_header>
  <id_info>
    <org_study_id>GA1210</org_study_id>
    <nct_id>NCT01869491</nct_id>
  </id_info>
  <brief_title>Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to provide evidence that Compound Sodium Alginate Double Action
      Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and
      dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in GERD dimension</measure>
    <time_frame>7 days</time_frame>
    <description>The primary study endpoint is to compare the change from baseline in RDQ symptom scores for the GERD dimension (heartburn and regurgitation) after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in RDQ scores for dyspepsia dimension</measure>
    <time_frame>7 days</time_frame>
    <description>Comparison between the two cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) for a 7-day treatment period for change from baseline in RDQ scores for dyspepsia dimension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1107</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Sodium Alginate Double Action Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets, 2 tablets four times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Sodium Alginate Double Action Chewable Tablets</intervention_name>
    <description>2 tablets four times daily</description>
    <arm_group_label>Sodium Alginate Double Action Tablets</arm_group_label>
    <other_name>Gaviscon Double Action Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo tablets</intervention_name>
    <description>2 tablets four times daily</description>
    <arm_group_label>Matching placebo tablets</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current evidence of symptomatic GERD in accord with the Montreal definition

          -  Patients must have had troublesome heartburn and/or regurgitation (with or without
             dyspepsia symptoms) of at least mild or moderate intensity on at least five days
             during the week before the start of screening

        Exclusion Criteria:

          -  Patients who have a history of drug, solvent or alcohol abuse

          -  Patients who have suffered cardiac chest pain within the last year.

          -  Patients who have suffered a recent, significant unexplained weight loss of more than
             6 Kg in the last 6 months.

          -  Female patients of childbearing potential who, for the duration of the study, are
             either unwilling or unable to take adequate contraceptive precautions or are unwilling
             to be sexually abstinent

          -  Pregnancy or lactating mother.

          -  Patients with a history and/or symptom profile and/or discovered on endoscopy
             suggestive of the following: any other gastrointestinal (GI) disease, erosive GERD
             (Los Angeles [LA] classification grades C-D), Barrett's esophagus, acute peptic ulcer
             and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric
             stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious
             anaemia, indication for H-pylori eradication therapy, known gastro-intestinal bleeding
             (hematochezia or hematemesis) within the last 3 months, and severe diseases of other
             major body systems.

          -  Patients who were observed on endoscopy to have a hiatus hernia with a diameter which
             exceeds 3cm.

          -  Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for
             treating gastrointestinal disease, ulcermin or misoprostol preparations within 7 days
             prior to screening or throughout the study.

          -  Patients who have taken PPIs during the 10 days prior to screening, prokinetics or H2
             antagonists during the 5 days prior to screening or systemic glucocorticosteroids,
             non-steroidal anti-inflammatory drugs (NSAIDs, except for low dose aspirin which can
             be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or
             quadruple therapy for eradication of H-pylori during the last 28 days.

          -  Patients taking or requiring to take macrolide antibiotics, such as erythromycin,
             azithromycin, from the day before screening.

          -  Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.

          -  Patients with severe constipation, or history of intestinal obstruction.

          -  In the opinion of the Investigator, patients with damaged heart or kidney diseases and
             patients who require a low sodium diet.

          -  Any previous history of allergy or known intolerance to any of the IMP's
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Yaozong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University, School of Medicine, Shanghai, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RB Investigational Sites</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RB Investigational Sites</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal Reflux Disease</keyword>
  <keyword>GERD</keyword>
  <keyword>Dyspepsia</keyword>
  <keyword>Indigestion</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Acid reflux</keyword>
  <keyword>Compound Sodium Alginate Double Action Chewable Tablets</keyword>
  <keyword>Gaviscon Double Action Tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alginic acid</mesh_term>
    <mesh_term>Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

